![Nancy Miller-Rich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nancy Miller-Rich
Directeur/Membre du Conseil chez
ALDEYRA THERAPEUTICS, INC.
Fortune : 1 614 $ au 31/05/2026
Profil
Ms. Nancy Miller-Rich is an Independent Director at 4D Molecular Therapeutics, Inc., an Independent Director at Attralus, Inc., an Independent Director at Aldeyra Therapeutics, Inc., a Chief Executive Officer at Miller-Rich Associates LLC and an Executive Chairman at MedMelior, Inc. She is on the Board of Directors at 4D Molecular Therapeutics, Inc., Attralus, Inc., Aldeyra Therapeutics, Inc., Global Alliance for TB Drug Development and Helio Vision, Inc. Ms. Miller-Rich was previously employed as a Chairman by BioTheryX, Inc., an Independent Director by Kadmon Holdings, Inc., a Co-Founder by Ten63 Therapeutics, Inc., an Independent Director by Intercept Pharmaceuticals, Inc., an Independent Non-Executive Director by UDG Healthcare Ltd. (Dublin), a SVP-Global Human Health Business Development by Merck & Co., Inc., and a SVP-Global Human Health Business Development by Schering-Plough Corp.
She received her undergraduate degree from Ithaca College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/06/2026 | 922 ( 0 % ) | 1 614 $ | 31/05/2026 | |
| 20/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Nancy Miller-Rich
| Sociétés | Poste | Début |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/01/2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 18/11/2020 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Directeur/Membre du Conseil | 06/03/2018 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Engage in business of developing therapeutics for women | Président | - |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Directeur/Membre du Conseil | 01/07/2020 |
Miller-Rich Associates LLC | Directeur Général | 01/01/2017 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Directeur/Membre du Conseil | - |
Anciens postes connus de Nancy Miller-Rich
| Sociétés | Poste | Fin |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/11/2023 |
BioTheryX, Inc.
 BioTheryX, Inc. Packaged SoftwareTechnology Services Operates as a biopharmaceutical company that develops protein degradation platform | Président | 01/04/2023 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Nancy Miller-Rich
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Health Technology |
Aldeyra Therapeutics, Inc.
 Aldeyra Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for eye diseases | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Packaged SoftwareTechnology Services Operates as a biopharmaceutical company that develops protein degradation platform | Technology Services |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Discovers, develops and delivers transformative therapies for unmet medical needs | Health Technology |
UDG Healthcare Ltd. (Dublin)
 UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services Provides healthcare advisory, communications, commercial, clinical and packaging services | Commercial Services |
Ithaca College
 Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Engage in business of developing therapeutics for women | Health Technology |
TEN63 Therapeutics
 TEN63 Therapeutics Packaged SoftwareTechnology Services Develops AI platform for drug discovery | Technology Services |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
Miller-Rich Associates LLC |
